Clinical Trial Detail

NCT ID NCT03386513
Title Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications

acute myeloid leukemia

acute lymphoblastic leukemia

myeloproliferative neoplasm

hematologic cancer

chronic myeloid leukemia

aggressive NK-cell leukemia

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

IMGN632

Age Groups: senior adult

No variant requirements are available.